Showing results (361-370 of 375) with videos related to
Sort By:
Pageof 38
Cancer Research Communications|March 27, 2023
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair DefectsMansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, et al.Journal of the National Cancer Institute|September 30, 2024
Automated patient selection and care coaches to increase advance care planning for patients with cancerMichael F Gensheimer, Winifred Teuteberg, Manali I Patel, et al.Therapeutic Advances in Medical Oncology|September 29, 2022
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trialMaria-Pilar Barretina-Ginesta, Bradley J Monk, Sileny Han, et al.Journal of the American College of Cardiology|March 18, 2017
Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume OverloadMarvin A Konstam, Michael Kiernan, Arthur Chandler, et al.JAMA Cardiology|November 3, 2021
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical TrialDouglas L Mann, Michael M Givertz, Justin M Vader, et al.Circulation. Cardiovascular Quality and Outcomes|January 12, 2021
The Cardiovascular Quality Improvement and Care Innovation Consortium: Inception of a Multicenter Collaborative to Improve Cardiovascular Care, Steven M Bradley, Srinath Adusumalli, et al.Cureus|September 24, 2025
Surgical Outcomes of Open, Laparoscopic, and Robotic-Assisted Approaches for Stage I Endometrial Cancer: Insights From a Real-World Study by the Indian Gynecologic-Onco Study GroupVandana Jain, Jaydip Bhaumik, Rama Joshi, et al.Gynecologic Oncology|June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialGiorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.JACC. Heart Failure|July 10, 2020
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE TrialDouglas L Mann, Stephen J Greene, Michael M Givertz, et al.Cancer|April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialMansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.Pageof 38